Abstract
Nanosuspension is a term that can be used to describe a colloidal dispersion of nanosized droplets of the drug in an aqueous medium with a size below 1 μm. Drug nanoparticles are one of the most significant methods to reduce the constituent part diameter and increase surface area, improving the dissolution and oral bioavailability of hydrophobic medicines, enhancing drug dissolution rate and bioavailability. Nanoparticles are produced using appropriate techniques for drug delivery applications and administered via various routes, including oral, topical, parenteral, ophthalmic, and pulmonary. Overactive bladder (OAB) affects around 16% of adults and is more common as people become older. It causes a variety of symptoms, including urgency, incontinence, urine frequency, and nocturia. DH. It is newly drug used to treat complicated OAB. It has a higher selectivity for the bladder’s muscarinic receptors. After intravenous and immediate-release oral dose forms. It suffers from extensive first-pass metabolism with a short elimination half-life and ranging between three to four hours). The current research focused on creating an extended-release dosage form utilizing Eudragit RS100. The solvent/anti-solvent precipitation method was used to make darifenacine nanoparticles. A certain quantity of medication was dissolved in a water-miscible solvent (methanol), then poured at a specific speed into water containing stabilizer on a magnetic stirrer for a 1/2-hour; after that, the resulted product was sonicated at 37°C for 15 minutes. The physicochemical interaction among medication with additives was explored utilizing fourier transform infrared spectroscopy (FTIR) and differential scanning calorimetric (DSC). The particle size and zeta potential of the generated nanosuspension were calculated.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have